Clinical Trial Update: Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) [Phase 2]

View source ↗

Summary

Phase 2 trial MK-6482-016 evaluating pembrolizumab plus lenvatinib in combination with belzutifan for solid tumors is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Belzutifan (belzutifan)
• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasm Malignant | Phase 2 | Status: ACTIVE_NOT_RECRUITING